NCT06764160 2026-01-15
ECU-MG-304
Alexion Pharmaceuticals, Inc.
Phase 3 Completed
Clinical Trials
6 trialsNCT03759366 2024-12-11
A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)
Alexion Pharmaceuticals, Inc.
Phase 3 Completed
NCT02003144 2022-08-23
An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients
Alexion Pharmaceuticals, Inc.
Phase 3 Completed
NCT02301624 2020-02-05
Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 3 Completed
NCT01997229 2019-07-16
Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)
Alexion Pharmaceuticals, Inc.
Phase 3 Completed
NCT01892345 2019-06-26
A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)
Alexion Pharmaceuticals, Inc.
Phase 3 Terminated